New diabetes pill orforglipron achieves uniform weight loss for women of all ages

https://www.news-medical.net/news/20260928/New-diabetes-pill-orforglipron-achieves-uniform-weight-loss-for-women-of-all-ages.aspx New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal. The study is by Dr Hunter Thomas Hoffman, Eli Lilly and Company, Indianapolis, IN, USA – the sponsor of the study and manufacturer of orforglipron – and colleagues. Obesity, a chronic progressive disease, is exacerbated by oestrogen deficiency during menopause. Orforglipron, an oral small-molecule, non-peptide GLP-1 receptor agonist, was associated with significant body weight (BW) reductions in ATTAIN-1 and -2 studies, one of which looked at people living with overweight or obesity but not diabetes (ATTAIN-1) and the other with both conditions (ATTAIN-2). This additional analysis evaluates orforglipron's effect on BW in women by menopausal stage.